The price of Boston Scientific Corp (NYSE:BSX) shares last traded on Wall Street fell -0.75% to $100.80.
BSX stock price is now 2.55% away from the 50-day moving average and 17.93% away from the 200-day moving average. The market capitalization of the company currently stands at $148.76B.
With the price target maintained at $108, Deutsche Bank recently Upgraded its rating from Hold to Buy for Boston Scientific Corp (NYSE: BSX). , while ‘Goldman’ rates the stock as ‘Buy’
In other news, Mirviss Jeffrey B., EVP&Pres, Periph Intervent sold 4,675 shares of the company’s stock on Feb 24 ’25. The stock was sold for $487,369 at an average price of $104.25. Upon completion of the transaction, the EVP&Pres, Periph Intervent now directly owns 28,454 shares in the company, valued at $2.87 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 25 ’25, EVP&Pres, Periph Intervent Mirviss Jeffrey B. sold 2,688 shares of the business’s stock. A total of $279,552 was realized by selling the stock at an average price of $104.00. This leaves the insider owning 25,766 shares of the company worth $2.6 million. A total of 0.47% of the company’s stock is owned by insiders.
During the past 12 months, Boston Scientific Corp has had a low of $65.52 and a high of $107.17. As of last week, the company has a debt-to-equity ratio of 0.52, a current ratio of 1.08, and a quick ratio of 0.64.
The net profit margin was 11.07% and return on equity was 9.03% for BSX. The company reported revenue of $4.56 billion for the quarter, compared to $3.73 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.47 percent.
